Clinical trials
Relapsed or Refractory Multiple Myeloma clinical trials
Below are recruiting relapsed or refractory multiple myeloma clinical trials, each written for real people, not researchers. We’re tracking 1,295 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04024761RecruitingPhase 1
NK cell therapy for leukemia relapse after transplant
This Phase 1 study tests whether an infusion of special immune cells (NK cells) from a donor can help control leukemia or related blood cancers that come back or do not fully go away after a stem cell transplant. It also uses short chemotherapy to “make space” for the NK cells to work, and IL-2 to help them function.
Boston, MassachusettsAges 12 years+ - NCT04050345Recruiting
Blood test to spot DNA changes after early colon cancer surgery
This study checks a “cell-free tumor DNA” blood test to see if cancer mutations can predict relapse after surgery for early colorectal cancer. If results look risky, they may help guide closer follow-up and future treatment decisions.
Milton Keynes, BuckinghamshireAges 18 years+ - NCT04119024RecruitingPhase 1
Gene-edited immune cells for advanced melanoma or solid tumors
This Phase 1 study tests a gene-modified immune cell treatment for advanced cancers that don’t have standard curative options. It may help by attacking cancer cells that show a specific marker called IL13Rα2 after patients receive “conditioning” chemotherapy to prepare the immune system.
Duarte, CaliforniaAges 18–75 - NCT04322318RecruitingPhase 2
Study of combination chemotherapy for Wilms tumor in children
This Phase 2 trial tests combination chemotherapy for children with certain types of Wilms tumor—either newly diagnosed diffuse anaplastic Wilms tumor or favorable Wilms tumor that has come back. The goal is to see how well the treatment controls the tumor and is tolerable for children.
Birmingham, AlabamaAges Up to 30 years - NCT04424719Recruiting
Follow-up study for high-risk eye melanoma after treatment
This study follows people with high-risk uveal (eye) melanoma after their initial treatment to better understand relapse risk. It may help your care team track you more closely using scheduled visits and blood tests.
ParisAges 18 years+ - NCT04546399RecruitingPhase 2
Blinatumomab with or without nivolumab for first relapse ALL
This study compares blinatumomab alone versus blinatumomab plus nivolumab in young people whose B-cell ALL has returned for the first time. It aims to see whether adding nivolumab improves control of the leukemia after relapse.
Birmingham, AlabamaAges 1–30 - NCT04561557RecruitingEarly Phase 1
Cell therapy for relapsing nervous system autoimmune diseases
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
Wuhan, HubeiAges 18–75 - NCT04587856Recruiting
Study why blood cancer returns after donor stem cell transplant
This study looks at why a bone marrow disorder (MDS) can come back after a donor stem cell transplant. It may help researchers understand relapse, which could improve future care for people getting transplants.
BariAges 18 years+ - NCT04625907RecruitingPhase 1/Phase 2
Study testing treatment options for children and adults with RMS
This study tests different treatment approaches for rhabdomyosarcoma (RMS) in children and adults, including newly diagnosed high-risk cases, people needing radiotherapy, and people whose RMS has returned. It’s designed to find safer dosing and more effective therapy while checking whether participants can proceed based on health and timing requirements.
BrisbaneAges Any age - NCT04650321RecruitingPhase 4
Home infusions of ocrelizumab for some people with MS
This study looks at giving ocrelizumab treatments at home instead of in a clinic for people with MS. It’s meant to see if this approach is practical and acceptable while you keep receiving a medicine your MS doctor thinks you should continue.
Centennial, ColoradoAges 18–55 - NCT04678401RecruitingPhase 1
Trial tests transplant using a half-matched donor for high-risk leukemia
This Phase 1 trial tests a special bone marrow transplant using a related “half-matched” donor (haploidentical), without a specific immune-suppressing medicine (“IS-free”). It’s for adults with certain high-risk AML or MDS to see if this approach can improve control of the disease while tracking safety.
Boston, MassachusettsAges 18–75 - NCT04758000RecruitingPhase 2
Metformin after bone cancer treatment to prevent relapse
This Phase 2 study tests whether taking metformin after surgery and chemotherapy can reduce the risk of bone cancer coming back in people at high risk of relapse. You may be eligible if you have osteosarcoma or Ewing sarcoma that is not currently spread and you meet specific lab and health criteria.
BolognaAges 14 years+ - NCT04794777RecruitingPhase 3
Tests targeted scans and rescue radiation for returning prostate cancer
This trial studies whether a targeted scan (PSMA PET/CT) can help doctors choose the best “salvage” radiation treatment when prostate cancer comes back by PSA blood tests after surgery. It may help some people avoid under- or over-treating the areas where the cancer is returning.
Gothenburg, GöteborgAges 18 years+ - NCT04838041RecruitingPhase 2
Testing stopping treatment after asciminib for CML relapse
This trial looks at whether people with chronic-phase CML who tried stopping a prior CML medicine and had to restart can later stop treatment again after a set period using asciminib. It checks whether you can stay in a deep remission (“free remission” without the usual CML tablets).
Detroit, MichiganAges 18 years+ - NCT04855695RecruitingPhase 1/Phase 2
Study for relapsed mantle cell lymphoma using targeted oral drugs
This Phase 1/2 study tests a combination of oral and antibody treatments for mantle cell lymphoma that has come back (relapsed) or did not respond (refractory). It aims to control the cancer and uses blood/tumor test results to guide some treatment timing for eligible participants.
Chicago, IllinoisAges 18 years+ - NCT04876339Recruiting
Sound-based training to improve walking after brain illness
This study tests whether using special sounds (sonification) during gait training can improve walking for people with stroke, Parkinson’s disease, or multiple sclerosis. It may help your walking speed, stamina (fatigue), and overall walking pattern.
PaviaAges Up to 80 years - NCT04914026Recruiting
MicroRNA test for testicular cancer diagnosis
This study looks at tiny genetic signals called microRNAs to see if they can help identify or track testicular cancer. It may help doctors recognize testicular cancer more accurately and decide what to do next.
BergenAges 18–70 - NCT04924868RecruitingPhase 3
Ursodeoxycholic acid to prevent gallstone pancreatitis returning
This trial tests whether ursodeoxycholic acid (a bile medicine) can help prevent complications from gallstone-related acute pancreatitis from coming back after you leave the hospital. It may help reduce repeat problems linked to gallstones, especially after an initial pancreatitis episode.
Santiago de Compostela, A coruñaAges 18 years+ - NCT04928677RecruitingPhase 1
Codrituzumab for children and young adults with GPC3-positive solid tumors
This Phase 1 study tests codrituzumab, an antibody medicine, in children and young adults whose solid tumor has come back or did not respond to standard treatment. It’s designed to see how the treatment works and how safe it is, especially for tumors that test positive for GPC3.
Los Angeles, CaliforniaAges 1–21 - NCT07003295RecruitingPhase 2
Glofitamab for mantle cell lymphoma that returned after CAR-T
This trial tests a new drug, glofitamab, for mantle cell lymphoma that came back or didn’t respond after CAR-T cell therapy. It aims to see if glofitamab can shrink or control the lymphoma.
Duarte, CaliforniaAges 18 years+ - NCT04972760RecruitingPhase 3
Baricitinib for active dermatomyositis in adults
This trial studies whether baricitinib can improve symptoms and test results in adults with active dermatomyositis (a muscle and skin inflammation disease). It’s for people whose disease is still active despite prior treatment or who have been recently diagnosed.
ParisAges 18–64 - NCT04990102RecruitingPhase 1/Phase 2
Trial drug to help prevent relapse in AML
This trial tests CPX-351 to help stop acute myeloid leukemia (AML) from coming back after you’ve reached remission. It’s for people who are not able to receive a stem cell transplant and need a new way to reduce relapse risk.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05011266RecruitingPhase 2/Phase 3
Buprenorphine plus naltrexone shot to prevent opioid relapse
This trial tests whether a combination of buprenorphine (through your care plan) and a monthly extended-release naltrexone (XR-NTX) shot can help prevent opioid relapse. It may help people who are ready to move toward a naltrexone-based relapse-prevention treatment after detox.
Rockville, MarylandAges 18–65 - NCT05019703RecruitingPhase 2
Atezolizumab plus cabozantinib for teen osteosarcoma
This trial studies a combination of two medicines—atezolizumab and cabozantinib—for teenagers and young adults with osteosarcoma that has come back or spread. It aims to slow or shrink the cancer and help control disease that can’t be fully removed with surgery.
Boston, MassachusettsAges 12 years+
Hear when a new Relapsed or Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory multiple myeloma?
- Yes. Clin2 currently lists 1,295 recruiting relapsed or refractory multiple myeloma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory multiple myeloma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.